5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 157.22▼ | 156.89▲ | 157.09▲ | 154.15▲ | 149.75▲ |
MA10 | 157.10▲ | 157.04▲ | 157.01▲ | 151.58▲ | 141.93▲ |
MA20 | 156.90▲ | 156.69▲ | 156.16▲ | 149.70▲ | 143.74▲ |
MA50 | 157.12▲ | 154.53▲ | 152.46▲ | 138.70▲ | 172.32▼ |
MA100 | 157.04▲ | 152.03▲ | 150.34▲ | 144.91▲ | 195.05▼ |
MA200 | 156.38▲ | 150.32▲ | 145.80▲ | 166.73▼ | 228.32▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.051▲ | -0.145▼ | -0.141▼ | 0.422▲ | 4.649▲ |
RSI | 53.747▲ | 56.653▲ | 59.483▲ | 67.598▲ | 52.283▲ |
STOCH | 76.085 | 32.879 | 62.915 | 75.575 | 87.651▲ |
WILL %R | -33.175 | -53.058 | -28.365 | -18.916▲ | -4.786▲ |
CCI | 92.998 | 61.586 | 74.190 | 164.362▲ | 105.957▲ |
Wednesday, July 02, 2025 02:39 AM
FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an overvaluation of 29.68%. See more.
|
Tuesday, July 01, 2025 06:21 AM
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Unicycive Therapeutics’ New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia ...
|
Monday, June 30, 2025 07:58 AM
FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate manufacturer in place.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
03/07/25 | 158.08 | 158.72 | 156.17 | 157.12 | 247,100 |
02/07/25 | 154.01 | 158.38 | 152.84 | 157.49 | 637,200 |
01/07/25 | 151.00 | 160.40 | 150.35 | 154.40 | 1,009,100 |
30/06/25 | 150.87 | 152.915 | 148.70 | 151.73 | 857,007 |
27/06/25 | 152.04 | 152.63 | 148.41 | 150.01 | 814,700 |
26/06/25 | 151.34 | 153.715 | 150.18 | 151.59 | 879,776 |
25/06/25 | 148.01 | 152.51 | 146.00 | 150.21 | 747,400 |
24/06/25 | 149.01 | 149.675 | 146.84 | 148.40 | 823,845 |
23/06/25 | 146.21 | 148.32 | 144.37 | 147.38 | 1,487,900 |
20/06/25 | 146.09 | 147.74 | 144.36 | 147.45 | 1,542,800 |
|
|
||||
|
|
||||
|
|